Journal Article
. 2008 Dec; 100(1):113-7.
doi: 10.1038/sj.bjc.6604812.

Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40

E Oflazoglu 1 I J Stone  L Brown  K A Gordon  N van Rooijen  M Jonas  C-L Law  I S Grewal  H-P Gerber  
  • PMID: 19066610
  •     19 References
  •     28 citations


SGN-40 is a therapeutic antibody targeting CD40, which induces potent anti-lymphoma activities via direct apoptotic signalling cells and by cell-mediated cytotoxicity. Here we show antibody-dependent cellular phagocytosis (ADCP) by macrophages to contribute significantly to the therapeutic activities and that the antitumour effects of SGN-40 depend on Fc interactions.

Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity.
Thomas F Tedder, Aris Baras, Yan Xiu.
Springer Semin Immunopathol, 2006 Nov 09; 28(4). PMID: 17091246
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
Wen-Kai Weng, Ronald Levy.
J Clin Oncol, 2003 Sep 17; 21(21). PMID: 12975461
Highly Cited.
Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30.
Ezogelin Oflazoglu, Ivan J Stone, +4 authors, Hans-Peter Gerber.
Blood, 2007 Oct 03; 110(13). PMID: 17909075
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications.
Yu-Tzu Tai, Laurence P Catley, +11 authors, Kenneth C Anderson.
Cancer Res, 2004 Apr 17; 64(8). PMID: 15087402
CD40 expression in Hodgkin's disease.
J T O'Grady, S Stewart, +2 authors, A S Krajewski.
Am J Pathol, 1994 Jan 01; 144(1). PMID: 7507299    Free PMC article.
Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities.
K L Armour, M R Clark, A G Hadley, L M Williamson.
Eur J Immunol, 1999 Aug 24; 29(8). PMID: 10458776
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
Yu-Tzu Tai, Xian-Feng Li, +13 authors, Kenneth C Anderson.
Cancer Res, 2005 Dec 17; 65(24). PMID: 16357183
Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype.
H R Koene, M Kleijer, +3 authors, M de Haas.
Blood, 1997 Aug 01; 90(3). PMID: 9242542
Highly Cited.
The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Robert Marcus, Anton Hagenbeek.
Eur J Haematol Suppl, 2007 Jan 09; (67). PMID: 17206982
CD40-CD40 ligand.
C van Kooten, J Banchereau.
J Leukoc Biol, 2000 Jan 27; 67(1). PMID: 10647992
Highly Cited. Review.
Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells.
John O Richards, Sher Karki, +3 authors, John R Desjarlais.
Mol Cancer Ther, 2008 Aug 30; 7(8). PMID: 18723496
Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions.
G Urlaub, P J Mitchell, +4 authors, J Hamlin.
Somat Cell Mol Genet, 1986 Nov 01; 12(6). PMID: 3024331
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.
Guillaume Cartron, Laurent Dacheux, +4 authors, Hervé Watier.
Blood, 2002 Jan 25; 99(3). PMID: 11806974
Highly Cited.
Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells.
F M Uckun, K Gajl-Peczalska, +3 authors, J A Ledbetter.
Blood, 1990 Dec 15; 76(12). PMID: 1702326
Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.
Che-Leung Law, Kristine A Gordon, +9 authors, Iqbal S Grewal.
Cancer Res, 2005 Sep 17; 65(18). PMID: 16166310
High-level expression of proteins in mammalian cells using transcription regulatory sequences from the Chinese hamster EF-1alpha gene.
Jennifer Running Deer, Daniel S Allison.
Biotechnol Prog, 2004 Jun 05; 20(3). PMID: 15176895
Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia.
Sherif S Farag, Ian W Flinn, +3 authors, John C Byrd.
Blood, 2003 Oct 18; 103(4). PMID: 14563637
CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line.
J J Westendorf, G J Ahmann, +5 authors, D F Jelinek.
J Immunol, 1994 Jan 01; 152(1). PMID: 7504707
Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities.
Julie A McEarchern, Ezogelin Oflazoglu, +10 authors, Che-Leung Law.
Blood, 2006 Oct 14; 109(3). PMID: 17038522
Monoclonal antibodies: versatile platforms for cancer immunotherapy.
Louis M Weiner, Rishi Surana, Shangzi Wang.
Nat Rev Immunol, 2010 Apr 24; 10(5). PMID: 20414205    Free PMC article.
Highly Cited. Review.
Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy.
Brandon Kwong, Haipeng Liu, Darrell J Irvine.
Biomaterials, 2011 Apr 26; 32(22). PMID: 21514665    Free PMC article.
The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge.
Randall J Brezski, Allison Oberholtzer, Brandy Strake, Robert E Jordan.
MAbs, 2011 Nov 30; 3(6). PMID: 22123056    Free PMC article.
Monoclonal antibodies for the treatment of cancer.
Casey W Shuptrine, Rishi Surana, Louis M Weiner.
Semin Cancer Biol, 2012 Jan 17; 22(1). PMID: 22245472    Free PMC article.
Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.
Yu-Tzu Tai, Holly M Horton, +12 authors, Umesh S Muchhal.
Blood, 2012 Jan 17; 119(9). PMID: 22246035    Free PMC article.
T-cell-independent antitumor effects of CD40 ligation.
Alexander L Rakhmilevich, Kory L Alderson, Paul M Sondel.
Int Rev Immunol, 2012 Jul 19; 31(4). PMID: 22804571    Free PMC article.
Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG.
Kory L Alderson, Mitchell Luangrath, +4 authors, Paul M Sondel.
Cancer Immunol Immunother, 2012 Nov 16; 62(4). PMID: 23151945    Free PMC article.
Fcγ receptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies.
Steven E Justiniano, Saranya Elavazhagan, +12 authors, Susheela Tridandapani.
J Biol Chem, 2013 Aug 02; 288(37). PMID: 23902770    Free PMC article.
Engineered protease-resistant antibodies with selectable cell-killing functions.
Michelle Kinder, Allison R Greenplate, +9 authors, Randall J Brezski.
J Biol Chem, 2013 Aug 30; 288(43). PMID: 23986451    Free PMC article.
TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.
Yoshikane Kikushige, Toshihiro Miyamoto.
Int J Hematol, 2013 Sep 21; 98(6). PMID: 24046178
Macrophages eliminate circulating tumor cells after monoclonal antibody therapy.
Nuray Gül, Liane Babes, +7 authors, Marjolein van Egmond.
J Clin Invest, 2014 Jan 17; 124(2). PMID: 24430180    Free PMC article.
Highly Cited.
Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ.
Jens H W Pahl, Kitty M C Kwappenberg, +10 authors, Marco W Schilham.
J Exp Clin Cancer Res, 2014 Mar 13; 33. PMID: 24612598    Free PMC article.
CD40 expression and its prognostic significance in human gastric carcinoma.
Jing Guo, Jia-Jia Xiao, Xiaoli Zhang, Kai-Xi Fan.
Med Oncol, 2015 Feb 11; 32(3). PMID: 25665853
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.
Marije B Overdijk, Sandra Verploegen, +8 authors, Paul W H I Parren.
MAbs, 2015 Mar 12; 7(2). PMID: 25760767    Free PMC article.
Highly Cited.
An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Michelle Kinder, Allison R Greenplate, +2 authors, Randall J Brezski.
MAbs, 2015 May 02; 7(3). PMID: 25933349    Free PMC article.
Toll-like Receptor 4 Ligands Down-regulate Fcγ Receptor IIb (FcγRIIb) via MARCH3 Protein-mediated Ubiquitination.
Kavin Fatehchand, Li Ren, +7 authors, Jonathan P Butchar.
J Biol Chem, 2015 Dec 24; 291(8). PMID: 26694610    Free PMC article.
Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.
Gregory L Beatty, Yan Li, Kristen B Long.
Expert Rev Anticancer Ther, 2016 Dec 09; 17(2). PMID: 27927088    Free PMC article.
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Alexander H Staudacher, Michael P Brown.
Br J Cancer, 2017 Oct 25; 117(12). PMID: 29065110    Free PMC article.
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.
Carlos Cuesta-Mateos, Ana Alcaraz-Serna, Beatriz Somovilla-Crespo, Cecilia Muñoz-Calleja.
Front Immunol, 2018 Feb 02; 8. PMID: 29387053    Free PMC article.
Redox control of cancer cell destruction.
Csaba Hegedűs, Katalin Kovács, +6 authors, László Virág.
Redox Biol, 2018 Feb 25; 16. PMID: 29477046    Free PMC article.
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody.
Randi B Gombos, Ana Gonzalez, +24 authors, Nicholas S Wilson.
PLoS One, 2018 Apr 05; 13(4). PMID: 29617360    Free PMC article.
Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy.
Lekh N Dahal, Chie-Yin Huang, +10 authors, Stephen A Beers.
J Immunol, 2018 Jul 13; 201(4). PMID: 29997125    Free PMC article.
ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile.
Steven E Kauder, Tracy C Kuo, +9 authors, Hong I Wan.
PLoS One, 2018 Aug 23; 13(8). PMID: 30133535    Free PMC article.
Boosting therapeutic potency of antibodies by taming Fc domain functions.
Tae Hyun Kang, Sang Taek Jung.
Exp Mol Med, 2019 Nov 19; 51(11). PMID: 31735912    Free PMC article.
An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIaV158 Reveals That Ligation of FcγRIIIa Mediates Potent Antibody Dependent Cellular Phagocytosis With GM-CSF-Differentiated Macrophages.
Tae Hyun Kang, Chang-Han Lee, +7 authors, George Georgiou.
Front Immunol, 2019 Apr 16; 10. PMID: 30984171    Free PMC article.
Reprogramming the Constant Region of Immunoglobulin G Subclasses for Enhanced Therapeutic Potency against Cancer.
Tae Hyun Kang, Sang Taek Jung.
Biomolecules, 2020 Mar 04; 10(3). PMID: 32121592    Free PMC article.
Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies.
Da-Ke Li, Wen Wang.
Oncol Lett, 2020 Sep 17; 20(5). PMID: 32934743    Free PMC article.
Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials.
Haiying Lu, Qiaodan Zhou, +4 authors, Jianyou Shi.
Signal Transduct Target Ther, 2020 Sep 25; 5(1). PMID: 32968059    Free PMC article.